Not indicated for long term treatment of paed patients w/ growth failure due to Prader-Willi syndrome w/ risk factors (severe obesity, history of upper airway obstruction, sleep apnoea or unidentified resp infection). Funduscopy for papilloedema is recommended in the event of severe or recurring headache, visual problems & nausea/vomiting; if papilloedema is confirmed consider benign intracranial HTN diagnosis. Carefully monitor intracranial HTN symptoms if GH treatment is restarted. Possible leukemia. Test for Ab in any patient who fails to respond to therapy. Monitor thyroid function. Closely monitor standard replacement therapy in patients w/ hypopituitarism. Monitor for evidence of glucose intolerance in patient w/ DM or in those w/ family history predisposition for the disease. Frequently monitor for progression or recurrence of underlying disease process in patients w/ GH deficiency secondary to intracranial lesion; discontinue therapy if progression or recurrence of the lesion occurs. Monitor for signs & symptoms of relapse in patients w/ previous malignant diseases. Monitor for signs of scoliosis during treatment. Slipped capital femoral epiphysis may occur more frequently in patients w/ endocrine disorders. Evaluate patient who develops limp or complains of hip or knee pain. Weigh benefit/risk ratio in acutely critically ill patients. Consider pancreatitis especially in childn who develop abdominal pain. Solvent contains benzyl alcohol. Not recommended during pregnancy & in woman of childbearing potential not using contraception. Lactation. Infant & childn up to 3 yr.
Sign Out
